Our research concerns high risk populations with specific characteristics (e.g. elderly or ICU patients), benefit risk assessment of biologics in any indication, healthcare assessment with a particular focus on the underlying processes of patient management (e.g. admission, hospital stay strictly speaking, or discharge elements) and its consequences on drug benefit/risk.
Our research is based on the use of field data and healthcare administrative databases or warehouses of in-hospital clinical data, the use or development of several methods, often combined, including patient reported outcomes and e-cohorts for taking the patient perspective into account, various designs for comparative ER and pharmacoepidemiology, systematic reviews and meta-analyses, pragmatic trials, cohorts, case-only designs) and associated statistical modeling / analyses (e.g., causal inference in observational data, modeling of drug exposure, medico-economic evaluation, meta-epidemiological studies).
A large part of our research was endorsed or funded by French health institutions (HAS, OMEDIT, CNAMT, ARS, ANSM, ministry of Health) attesting the interest of public decision-makers for our research and our capacity to translate research into practice and policy.
This multidisciplinary team will involve epidemiologists, biostatisticians, pharmacists and clinicians (gastroenterologists, rheumatologists, geriatricians, dermatologists, intensivists).